Jalisi Scharukh, Ainsworth Tiffiny, Lavalley Michael
Department of Otolaryngology, Head and Neck Surgery, Boston University School of Medicine, 820 Harrison Avenue, FGH4, Boston MA 02118, USA.
J Thyroid Res. 2010 Jul 26;2010:325602. doi: 10.4061/2010/325602.
Objective. To evaluate the prognosis of tall cell variant (TCV) compared to usual variant (UV) papillary thyroid cancer by comparing disease-related mortality and recurrence data from published studies. Methods. Ovid MEDLINE keyword search using "tall cell variant papillary thyroid cancer" was used to identify studies published in English that calculated disease-related mortality and recurrence rates for both TCV and UV. Results. A total of 131 cases of tall cell variant papillary thyroid cancer were reviewed. The combined odds ratio of recurrence for TCV compared to UV is 4.50 with a 95% confidence interval from 2.90 to 6.99. For disease-related mortality, the combined odds ratio for TCV was compared to UV of 14.28 with a 95% confidence interval from 8.01 to 25.46. Conclusion. Currently published data suggests that TCV is a negative prognostic indicator in papillary thyroid cancer and requires aggressive therapy. This meta-analysis provides the largest prognostic data series on TCV in the literature and clearly identifies the need for accurate pathological identification of TCV and its further study as an independent prognostic factor.
目的。通过比较已发表研究中的疾病相关死亡率和复发数据，评估高细胞变异型（TCV）与普通变异型（UV）甲状腺乳头状癌的预后。方法。使用“高细胞变异型甲状腺乳头状癌”在Ovid MEDLINE上进行关键词搜索，以识别用英文发表的计算了TCV和UV的疾病相关死亡率及复发率的研究。结果。共回顾了131例高细胞变异型甲状腺乳头状癌病例。与UV相比，TCV复发的合并比值比为4.50，95%置信区间为2.90至6.99。对于疾病相关死亡率，TCV与UV相比的合并比值比为14.28，95%置信区间为8.01至25.46。结论。目前已发表的数据表明，TCV是甲状腺乳头状癌的不良预后指标，需要积极治疗。这项荟萃分析提供了文献中关于TCV的最大预后数据系列，并明确指出需要对TCV进行准确的病理识别，并将其作为一个独立的预后因素进行进一步研究。
